Strongbridge Biopharma Stock Price - SBBP

-0.06 (-1.75%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Strongbridge Biopharma PLC SBBP NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.06 -1.75% 3.36 3.28 3.4036 3.40 3.42 10:09:55
Bid Price Ask Price Spread Spread % News
3.35 3.38 0.03 0.89% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
248 42,321 $ 3.38 $ 143,005 368,155 1.43 - 3.89
Last Trade Time Type Quantity Stock Price Currency
10:10:18 64 $ 3.38 USD

Strongbridge Biopharma Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 182.27M 54.25M 53.51M $ 21.71M $ - -1.14 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Strongbridge Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SBBP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.873.893.283.66496,062-0.51-13.18%
1 Month2.713.892.563.29407,3570.6523.99%
3 Months2.323.891.502.55336,1591.0444.83%
6 Months1.853.891.502.54404,5371.5181.62%
1 Year2.823.891.432.43315,7140.5419.15%
3 Years4.7929.251.434.67301,300-1.43-29.88%
5 Years13.0014.301.434.65210,644-9.64-74.15%

Strongbridge Biopharma Description

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.